European Commission solidifies vaccine manufacturing plans to prepare for future health emergencies

The Eu­ro­pean Com­mis­sion struck deals with a hand­ful of con­trac­tors, in­clud­ing Pfiz­er, to se­cure “suf­fi­cient and ag­ile man­u­fac­tur­ing ca­pac­i­ties” for a va­ri­ety of vac­cine types in case of fu­ture pub­lic health emer­gen­cies.

The con­tracts are part of the com­mis­sion’s long-stand­ing goal to cre­ate a net­work of “ever-warm pro­duc­tion ca­pac­i­ties” for vac­cine and drug man­u­fac­tur­ing in Eu­rope. They were first re­port­ed by Reuters. Un­der the frame­work, the EC’s Eu­ro­pean Health and Dig­i­tal Ex­ec­u­tive Agency would have ac­cess up to 325 mil­lion vac­cine dos­es per year, it an­nounced Fri­day.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters